Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBX7455 for Recurrent Clostridioides Difficile Infection
NCT02981316Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2016
- Primary completion
- Jul 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label trial of RBX7455 in Clostridioides difficile infection (CDI) (4 arms), sponsored by Mayo Clinic. Primary endpoints: Time to recurrence of Clostridium Difficile Infection (CDI) at 8 weeks and Number of patients experiencing adverse events at 6 months. Started Nov 2016; status: completed.
02
Drugs
RBX7455
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02981316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02981316.